A Phase 2 interventional study of tests to determine HRD status in Ovarian Cancer, sponsored by Centre Francois Baclesse. Recruiting at 4 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-17.
Sponsored by Centre Francois Baclesse · Phase 2, Interventional, and Diagnostic
The study concerns patients with Invasive epithelial ovarian cancer, primary Fallopian tube carcinoma, ovarian-type peritoneal carcinoma, and with an indication of a first-line platinum-based chemotherapy.
To determine HRD status, 2 separate tests will be performed in the study:
If one or two tests identifies a HRD status :
a PARP inhibitor treatment may be initiated according to current recommendations
2,695 studies on the registry are indexed under Ovarian Neoplasms; 727 are open to participants now.
This study's planned enrollment of 88 is above the median of 60 across 2,030 interventional studies indexed under Ovarian Neoplasms.
Browse Ovarian Neoplasms studies →Centre Francois Baclesse is the lead sponsor of 109 studies on the registry; 26 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Tumor tissue must be available for HRD analyses (FFPE tissue block) and
Exclusion Criteria:
To determine HRD status on the tumor, 2 different tests will be used concomitantly
Genetic: tests to determine HRD status
Test Giscar AND test myChoice will be performed. If one or two tests identifies a HRD status : a PARP inhibitor treatment may be initiated according to current recommendations
Rate of platinum-sensitive ovarian cancer patients according to GIScar HRD signature (classified into HRD or HRP).
Evaluate Platinum-sensitivity patients (defined as absence of disease progression, according to RECIST 1.1 criteria, six months after a first-line platinum-based chemotherapy) correlated with Homologous Recombination status in tumor (HRD : Homologous Recombination deficient / HRP :Homologous Recombination Proficient)
Time frame: six months after the end of platinum-based chemotherapy
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Francois Baclesse